Impact of Pharmaceutical R&D Activity on Financial Flexibility and Bargaining Power

Gergő Tömöri (), Zoltán Bács, János Felföldi and Ildikó Orbán
Additional contact information
Gergő Tömöri: Institute of Accounting and Finance, Faculty of Economics and Business, University of Debrecen, H-4032 Debrecen, Hungary
Zoltán Bács: Institute of Accounting and Finance, Faculty of Economics and Business, University of Debrecen, H-4032 Debrecen, Hungary
János Felföldi: Institute of Applied Informatics and Logistics, Faculty of Economics and Business, University of Debrecen, H-4032 Debrecen, Hungary
Ildikó Orbán: Institute of Accounting and Finance, Faculty of Economics and Business, University of Debrecen, H-4032 Debrecen, Hungary

Economies, 2022, vol. 10, issue 11, 1-19

Abstract: The specificities of pharmaceutical companies’ activities also have an impact on their ability to improve profitability compared to other sectors. Examples of such specificities include patent rights on the medicines produced, which for a longer period of time prevent the entry of competing players, allowing sunk costs to be offset to some extent by advantages from using higher margins. The primary purpose of this study is to examine whether the bargaining power of R&D-engaged companies significantly affects the financial margin of their operations to a different extent than other pharmaceutical companies. This study examined panel data focused on companies with the highest turnover, while we filtered out differences in the effect due to different macroeconomic and development environments. Our findings are that while the gross profit was significantly influenced by the type of activity within the industry, this statement for the cash cycle is no longer justified. Our conclusion was that the difference between the engaged and non-engaged in R&D companies expressed mostly in the profitability ratios, besides that, countries which had different development policies and accounting systems also took impact on financial margins, although the relative GDP advantages disappeared when looking at intra-industry, cross-country movements.

Keywords: pharmaceutical industry; R&D; bargaining power; cash cycle; industry leaders; development policies; panel regression; profitability (search for similar items in EconPapers)
JEL-codes: E F I J O Q (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2227-7099/10/11/277/pdf (application/pdf)
https://www.mdpi.com/2227-7099/10/11/277/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jecomi:v:10:y:2022:i:11:p:277-:d:966415

Access Statistics for this article

Economies is currently edited by Ms. Hongyan Zhang

More articles in Economies from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().